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Both the Establishment and the Maintenance
of Neuronal Polarity Require Active Mechanisms:
Critical Roles of GSK-3 and Its Upstream Regulators
bosomes (Caceres et al., 1986; Dotti and Banker, 1987;
Goslin et al., 1988; Kleiman et al., 1990; Steward, 2002).
How neuronal polarity forms remains an interesting and
challenging question.
A well-established model for studying neuronal polar-
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breaking symmetry between stages 2 and 3 (Baas et
al., 1988; Ahmad et al., 1994). Molecules affecting actinAxon-dendrite polarity is a cardinal feature of neuronal
dynamics (Bradke and Dotti, 1999; but see also Ruthelmorphology essential for information flow. Here we
and Hollenbeck, 2000) or microtubule (MT) dynamicsreport a differential distribution of GSK-3 activity in
such as the collapsin response mediator protein-2the axon versus the dendrites. A constitutively active
(CRMP-2) (Inagaki et al., 2001; Fukata et al., 2002) regu-GSK-3 mutant inhibited axon formation, whereas
late the formation of axon-dendrite polarity. The evolu-multiple axons formed from a single neuron when
tionary conserved polarity complex composed of Par3/GSK-3 activity was reduced by pharmacological in-
Par6/aPKC was first found in C. elegans for their roleshibitors, a peptide inhibitor, or siRNAs. An active
in establishing the anterior-posterior polarity of the firstmechanism for maintaining neuronal polarity was re-
blastomere. Par3/Par6, as well as two small GTPasesvealed by the conversion of preexisting dendrites into
CDC42 and Rap1B, have recently been implicated inaxons upon GSK-3 inhibition. Biochemical and func-
the establishment of neuronal polarity in mammals (Shitional data show that the Akt kinase and the PTEN
et al., 2003; Nishimura et al., 2004b; Schwamborn andphosphatase are upstream of GSK-3 in determining
Puschel, 2004), though not in Drosophila (Rolls andneuronal polarity. Our results demonstrate that there
Doe, 2004).are active mechanisms for maintaining as well as es-
Glycogen synthase kinase-3 (GSK-3) is a multifunc-tablishing neuronal polarity, indicate that GSK-3 re-
tional serine (Ser)/threonine (Thr) kinase found ubiqui-lays signaling from Akt and PTEN to play critical roles
tously in eukaryotes (Embi et al., 1980; Woodgett, 1990).in neuronal polarity, and suggest that application of
Biochemically, GSK-3 has a high basal activity. Signal-GSK-3 inhibitors can be a novel approach to promote
ing pathways act by inhibitingGSK-3 activity. Phosphor-generation of new axons after neural injuries.
ylation of Ser at position 9 in GSK-3 inhibits the activi-
ties of GSK-3. GSK-3 is now known to be important in
Introduction
many biological processes, ranging from the canonical
Wnt signaling pathway, MT dynamics, to astrocyte mi-
The morphological polarity of neurons with crucial func- gration (Doble and Woodgett, 2003; Etienne-Manneville
tional implications is an essential component of the neu- and Hall, 2003).
ron doctrine established by Cajal (1911). Typically, a In the course of our work on axon guidance and neu-
neuron has a single axon and multiple dendrites. Den- ronal migration (Li et al., 1999; Wong et al., 2001; Liu et
drites usually receive signals, whereas the axon usually al., 2004), we considered the possibility that molecules
sends signals. Neuronal polarity is therefore important implicated in directional guidance could be involved in
for information processing and ensures unidirectional the development of neuronal polarity. We have obtained
signal flow in the nervous system or between the ner- evidence that GSK-3 played a regulatory role in estab-
vous and other systems. Work in the past two decades lishing and maintaining the axon-dendrite polarity. We
has shown that, in addition to the well-known morpho- further provide evidence that Akt and PTEN function
logical and functional polarities, there are alsomolecular upstream of GSK-3, while the accompanying paper
and organelle differences between the axons and the provides evidence that GSK-3 directly inactivates
dendrites, ranging from the preferential sorting of pro- CRMP-2 (Yoshimura et al., 2004 [this issue of Cell]).
teins andmRNAs to the differential distribution of polyri- Taken together, these findings indicate that GSK-3 is
a central regulator in a signaling pathway for neuronal
polarity.*Correspondence: y-rao@northwestern.edu
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Results eliminated by GSK-3 S9A (Figure 2F), perhaps due to
the redistribution of membrane and cytoplasmic materi-
als to the dendrites in the absence of an axon.Polarized Distribution of a Phosphorylated Form
Neither the wild-type GSK-3 nor a kinase-dead formof GSK-3 in Hippocampal Neurons
of GSK-3 affected axon-dendrite polarity (Figures 2CWe used hippocampal neurons to investigate a potential
and 2D). Wild-type GSK-3 reduced the length of axonsrole of GSK-3 in neuronal polarity. Hippocampal explants
(Figure 2E) but did not affect the number or the lengthwere isolated from embryonic day 18 (E18) rats and pyra-
of dendrites (Figure 2F).midal neurons were cultured (Banker and Cowan, 1977;
Dotti and Banker, 1987; Brewer et al., 1993).
To determine the distribution ofGSK-3 in hippocampal Formation of Multiple Axons after Inhibition
of GSK-3 Activity by Pharmacologicalneurons, we double-labeled neurons with an antibody
against total GSK-3 and another one against GSK-3 and Peptide Inhibitors and shRNAs
To further test for a role of GSK-3 in neuronal polarity, wephosphorylated at Ser 9 (referred to as pGSK-3 hereaf-
ter). GSK-3 was detected in all neurites, both in st. 2 used pharmacological inhibitors of GSK-3: SB216763,
SB415286 (Coghlan et al., 2000), and lithium chloridenonpolarized neurons (Figure 1A, in green) and in st. 3
polarized neurons (Figure 1B, in green). Interestingly, al- (LiCl). Hippocampal neurons were treated with each in-
hibitor or the control vehicle dimethyl sulfoxide (DMSO)though pGSK-3 is present in the tips of all neurites in st.
2 nonpolarized neurons (Figure 1A, in red and Figure 1C), and were cultured for 5 days. Both SB216763 and
SB415286 significantly decreased the number of neu-there is more pGSK-3 present in the tips of axons than
that in the tips of dendrites in st. 3 polarized neurons rons with a single axon but increased the number of
neurons with multiple axons (Figures 3A and 3B). LiCl(Figure 1B, in red and Figure 1D). The ratio of pGSK-3/
GSK-3 in the tips of st. 3 axons was significantly higher also caused the formation of multiple axons (Figure 3A),
although not as efficiently as the SB compounds (Figurethan that in the tips of st. 3 dendrites (Figure 1E).
GSK-3 also has a tyrosine phosphorylation site at 3B). The total number of neurites per neuron was not
significantly changed by SB216763, SB415286, or LiCl:216 (Tyr216) which increases GSK-3 activity (Hughes
et al., 1993;Wang et al., 1994). Nodifferential distribution they increased the number of axons and decreased the
number of dendrites (Figure 3C), indicating the formationof GSK-3 Tyr216 was detected in polarized hippocam-
pal neurons (Figure 1G). of axons at the expense of dendrites. Perhaps reflecting
a limited amount of membrane and cytoplasmic materi-
als during neurite outgrowth, the length of axons was
Inhibition of Axon Formation after Increasing shorter (Figure 3D) when multiple axons formed (all
GSK-3 Activity casesmarkedwith (M) in Figure 3D). Shortening of axons
To test for a functional role of GSK-3 in the formation was observed in all experiments, described later in this
of neuronal polarity, we used a constitutively active paper, when multiple axons formed. The length of den-
GSK-3 mutant S9A, in which Ser 9 was replaced with drites was not affected by the pharmacological inhibi-
alanine. Dissociated hippocampal neurons were trans- tors (data not shown).
fected with a plasmid for the green fluorescent protein We then used GID5-6, a peptide inhibitor of GSK-3
(GFP) or cotransfected with a plasmid for GFP and an- derived from the GSK-3 interaction domain of axin
other expressing GSK-3 S9A. Neurons were cultured (Hedgepeth et al., 1999). The control GID5-6LP contained
for 5 days before analysis of the axon-dendrite polarity a single amino acidmutation rendering it unable to inter-
by the relative length of axons versus dendrites and by act with GSK-3 (Hedgepeth et al., 1999; Zhang et al.,
staining with multiple specific antibodies. MAP2 is a 2003). GID5-6 led to multiple axon formation, as evi-
somatodendritic marker for all dendrites and the proxi- denced by multiple markers (Figures 3E and 3F and
mal part of axons (Caceres et al., 1984; Figure 2A), Supplemental Figure S1A at http://www.cell.com/cgi/
whereas the Tau-1, the anti-Synapsin I, and the anti- content/full/120/1/123/DC1/) and functional character-
GAP43 antibodies recognize the distal part of the axon ization by vesicle recycling (Figure 4F). The total number
(Mandell and Banker, 1996; Figure 2A). of neurites per neuron was not changed by GID5-6 (Fig-
Control hippocampal neurons (transfected with GFP ure 3G). Neurons transfected with GID5-6LP developed
alone) developed normal polarity, with most of them normal polarity (Figure 3F).
having a single axon and multiple dendrites and a small Finally, we used GSK-3HP1 and GSK-3HP2, two
percentage of neurons with either no or multiple axons short hairpin RNA (shRNA) constructs designed specifi-
(Figure 2C). GSK-3 S9A significantly inhibited neuronal cally against GSK-3 (Yu et al., 2003). The control con-
polarity (Figure 2C). Only 7.6% of control neurons has struct XASH3HP did not affect neuronal polarity (Figures
no axons,whereas approximately 49%of neurons trans- 4B and 4C, upper panels). Either GSK-3HP1 or GSK-
fected with GSK-3 S9A has no axon (p  0.001), as 3HP2 led to the formationofmultiple axons (seeFigures
exemplified by the neuron in Figure 2B that had no axon, 4A and 4B) at the expense of dendrites (Supplemental
with MAP2 in the entire length of every neurite. Without Figure S2A on the Cell website). When GSK-3 expres-
an axon, the axonal markers were mislocalized to all sion was examined (Figure 4C), reduction of GSK-3
neurites (Figure 2B). These neurites did not have recy- expression correlated with multiple axon formation.
cling of synaptic vesicles (Figure 4E), a functional char- Thus, GSK-3 expression was significantly reduced in
acteristic of axons. GFP-positive neurons that formed multiple axons, GSK-
GSK-3 S9A led to the absence of the axon but did 3HP1 (M) and GSK-3HP2 (M), but not significantly
not affect the number of dendrites (Figure 2D). Dendrites reduced in those that had a single axon, GSK-3HP1
(S) and GSK-3HP2 (S).were significantly longer in neurons when axons were
GSK-3 in Neuronal Polarity
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Figure 1. Distribution of GSK-3 and Phospho-GSK-3 (Ser 9) in Hippocampal Neurons
(A and B) Distribution of GSK-3 and pGSK-3 in st. 2 and st. 3 neurons, respectively. The scale bars are 20 m in this paper unless specified
otherwise. The small panels (scale bars of 5 m) on the right part of (B) are higher magnification pictures of the tips of axons and dendrites.
(C and D) Fluorescence intensity after anti-pGSK-3 immunostaining of the st. 2 and st. 3 neurons.
(E) pGSK-3 and GSK-3 levels in neurite tips of st. 3 neurons. Left panel: the average level of pGSK-3 in dendrites was normalized as 1.0 
0.13 (n  42); the relative level in axons is 5.8  0.38 (n  16; p  0.001). Right panel: the average pGSK-3/GSK-3 ratio in dendrites was
normalized as 1.0  0.11 (n  42), while that in axons was 2.4  0.16 (n  16, p  0.001).
(F) Specificity of anti-pGSK-3 (Ser 9) antibody, which does not recognize the GSK-3 S9A mutant transfected into HEK293 cells. IP:
immunoprecipitation. IB: immunoblotting.
(G) Distribution of pGSK-3 (Tyr216) and pGSK-3 (Ser 9) in st. 3 neurons.
Functionality of Multiple Axons Induced they have active synaptic vesicle recycling which can
be monitored by visualizing the FM4-64 dye uptake andby GSK-3 Inhibition
Although multiple axons are usually recognized by the release (Ryan et al., 1993). The FM dye was taken into
the axon of control hippocampal neurons after stimula-relative length and expression of molecular markers,
it is important to examine whether multiple axons are tion by potassium (K) (Figure 4D), whereas little FM4-64
was taken into the somatodendritic region (Figure 4D).functional. A basic feature of functional axons is that
Cell
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Figure 2. Inhibition of Axon Formation by a Constitutively Active Form of GSK-3
(A) GFP-transfected neurons showing expression of the dendrite marker (MAP2) and axon markers (Tau-1, GAP43, and Synapsin I). MAP2 is
localized in the soma, the dendrites, and the proximal part of the axon, while the axon markers are in the soma and the axon.
(B) Neurons transfected with GSK-3 S9A were stained with dendrite and axon markers. GSK-3 S9A transfected neurons lacked the axon,
and axonal markers were mislocalized to all remaining neurites.
(C) Quantification of polarity defects. The p values of differences between control and GSK-3 S9A were: 0.001 in the percent of neurons
with a single axon and 0.001 in those with no axons. Numbers were discussed in the text.
(D) Neurite numbers per neuron. GFP alone (n  56): 1.07  0.07 axon and 4.2  0.22 dendrites. GSK-3 (n  48): 1.04  0.04 axon and
3.95  0.27 dendrites. GSK-3 KD (n  54): 1.04  0.06 axon and 3.96  0.24 dendrites. The numbers of axons and dendrites of neurons
transfected with GFP and GSK-3 S9A were counted in two categories: (S) was neurons with single axons while (N) was neurons with no
axons. Separate analysis should give a more accurate account of the effect of GSK-3 S9A because not all neurons positive for GFP were
affected, most likely due to variations in GFP and GSK-3 S9A cotransfection efficiencies in different neurons.
(E) The average axon length of GFP-transfected neurons was normalized as 100%. The p values were 0.01 between the control and GSK-3
and 0.001 between the control and GSK-3 S9A (S).
(F) The average dendrite length of GFP-transfected neurons was normalized as 100%. The p value was0.01 between the control and GSK-3
S9A (N). Neurons were separately analyzed as into those with a single axon (S), those with no axon (N), or those with multiple axons (M).
The GSK-3 inhibitor GID5-6 caused the formation of neurons transfected with GSK-3 S9A with the same
assay and found that neurites remaining after GSK-3multiple axons positive for FM4-64 uptake after stimula-
tion by 45 mM K for 1 min (Figures 4F and 4G and S9A transfection were negative in uptake (Figures 4E
and 4G), confirming the earlier conclusion that GSK-3Supplemental Figure S2B on the Cell website), whereas
the dendrites did not take up the dye (Supplemental S9A eliminated axons.
Figure S2B on the Cell website and Figure 4G). Vesicle
recycling was observed: after the initial FM dye loading,
treatment with 90 mM K depleted it from two axons of Role of GSK-3 in Establishing Neuronal Polarity
Establishment of neuronal polarity can be studied bya single GID5-6 transfected neuron (Figure 4F). Similar
results were obtained with axons after GSK-3HP2 examining the effect of manipulations before or up to
st. 3, because most neurons reached st. 3 with axon-transfection (data not shown). These results indicate
that multiple axons induced by GSK-3 inhibition are dendrite polarity established after culturing for 48 hr
under the present conditions (Brewer et al., 1993). Tofunctional in vesicle recycling.
We also examined FM dye uptake by neurites from study the role of GSK-3 in establishing neuronal polar-
GSK-3 in Neuronal Polarity
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Figure 3. Formation of Multiple Axons upon GSK-3 Inhibition by Pharmacological and Peptide Inhibitors
(A) Neurons cultured in the presence of inhibitors (5 M SB216763, 10 M SB415286, or 1 mM LiCl) were examined for expression of Tau-1
(in green) and MAP2 (in red).
(B) Quantification of polarity defects. The p values were:0.001 between the control and SB216763,0.001 between the control and SB415286,
and 0.01 between the control and LiCl.
(C) Numbers of neurites per neuron. (N): no axon. (S): single axon. (M): multiple axons. The p values of the difference were: 0.001 between
DMSO and SB216763 (M), 0.001 between DMSO and SB415286 (M), and 0.001 between DMSO and LiCl (M).
(D) The average axon length of control (DMSO) neurons was normalized as 100%. The p values were: 0.001 between DMSO and SB216763
(M), 0.001 between DMSO and SB415286 (M), and 0.001 between DMSO and LiCl (M).
(E) Axon and dendrite markers in neurons transfected with GFP and GID5-6.
(F) Quantification of polarity defects. p values were:0.001 between GFP and GID5-6 (single axon),0.001 between GFP and GID5-6 (multiple
axons), 0.001 between GID5-6 and GID5-6LP (single axon), and 0.001 between GID 5-6 and GID 5-6LP (multiple axons).
(G) (S): neurons with single axons. (M): neurons with multiple axons. The p values were 0.001 between the GFP control and GID5-6.
ity, neurons were treated with SB415286 for the first 24 Neurons were cultured for 3 days to reach st. 3 before
being treated with SB415286 or the control DMSO forhr and then removed. Neurons were cultured until day
6 (144 hr) before polarity examination. SB415286 caused another 3 days (from 72 to 144 hr) and were fixed for
immunostaining on day 6. The majority of neuronsthe formation ofmultiple axons evenwhen it was applied
only for the first 24 hr (Figures 5A and 5B), indicating a treated with DMSO at day 3 developed normal polarity
by day 6 (Figure 5B). SB415286 treatment from 72 torole for GSK-3 in establishing axon-dendrite polarity.
We examined how GSK-3 inhibition affected the dy- 144 hr caused the formation of multiple axons (Figure
5A, lower panel and Figure 5B). It was almost as effectivenamics of neurite outgrowth by time lapse microscopy
recording of st. 2 neurons (Figure 5E, upper panels and as treatment from day 0 to day 6 (Figure 5B). These
results suggest that SB415286 could affect the mainte-Figure 5D). SB415286 significantly reduced the time
spent on retraction but increased the time spent both nance of neuronal polarity.
To further examine themaintenance role of GSK-3, weon pause and on growth (Figure 5E, lower panels and
Figure 5D). The extent of the increase in pausing is less recorded individual neurites before and after SB415286
treatment on day 3 and then followed them to day 6. Asthan that of the decrease in retraction. The net effect
was promoting the formationof longer neurites, presum- exemplified in Figure 5C, there was one long neurite on
day 3 (marked with a white arrow) and three shorterably axons.
neurites from the same neuron (marked with a white or
a yellow arrowhead) (Figure 5C, left panel). On day 6,Role of GSK-3 in Maintaining Neuronal Polarity
Tau-1 andMAP2 staining showed that the originally longThe availability of chemical inhibitors for GSK-3 allows
neurite (marked by the white arrow) was indeed an axonus to test whether there is an active mechanism for
(Figure 5C, right panel). Interestingly, an additional axonmaintaining neuronal polarity by applying them after the
establishment of neuronal polarity. was formed on day 6 (its end marked with the red arrow
Cell
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Figure 4. Effects of Specific siRNA Constructs on Hippocampal Neurons and Functional Characterization of Axons
(A) Localization of MAP2 in a neuron transfected with GFP and GSK-3HP2.
(B) Quantification of polarity defects. The p values were: 0.001 between GSK-3HP1 and XASH3HP and 0.001 between GSK-3HP2
and XASH3HP.
(C) The average GSK-3 level in the neurites of control neurons (XASH3HP) was normalized as 100%. The p values were: 0.001 between
the control and GSK-3 HP1 or HP2. (S): single axon. (M): multiple axons.
(D) A hippocampal neuron transfected with GFP was cultured for 7 days before being loaded with FM4-64 in 45 mM K for 1 min. The neuron
developed a single axon, which took up FM4-64. Boxed region in the left panel is shown in higher magnification in the lower right panels.
The soma and dendrites had little uptake of FM4-64 (upper right panels).
(E) A GSK-3 S9A transfected neuron took in little FM4-64 in their soma or any of the short neurites.
(F) A GID5-6 transfected neuron with multiple axons, which were positive in FM4-64 uptake (boxed region in the left panel). The
GSK-3 in Neuronal Polarity
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Figure 5. Roles of GSK-3 in Establishing and Maintaining Neuronal Polarity
(A) Neurons were treated with SB415286 from 0–24 hr, 72–144 hr, or 0–144 hr before being fixed for immunocytochemistry at day 6 (144 hr)
with Tau-1 (in green) and MAP2 (in red).
(B) Quantification of polarity defects. The p values were: 0.001 between DMSO and SB415286 for 0–24, or 72–144, or 0–144 hr.
(C) Conversion of a preexisting dendrite into an axon by SB415286. The left panel shows a neuron on day 3, with one presumptive axon (a
long neurite marked by a white arrow) and several dendrites (the tip of two dendrites marked by arrowheads). The middle and right panels
show the same neuron on day 6. The long neurite indicated by the white arrow was indeed an axon (as shown by Tau-1 staining). One of the
short neurites (indicated by the yellow arrowhead) in the leftmost panel on day 3 had grown by day 6 into an axon in the right panel. The red
arrow points to the tip of the new axon.
(D) Neurite dynamics. St. 2 neurons were imaged by time lapse microscopy at an interval of 10 min for 2 hr. The % of time spent by each
neurite on retraction, pause, or growth was recorded. The p values of differences between control and SB415286 were: retraction, 0.001;
pause, 0.05; and growth, 0.05.
(E) Dynamics of neurites from a representative neuron treated with DMSO (upper panel) or SB415286 (lower panel).
in themiddle and right panels of Figure 5C) fromaneurite Relationship of GSK-3 with Akt in the Formation
of Neuronal Polaritythat was short on day 3 (its end marked with the yellow
arrowhead in the left panel of Figure 5C). These results Ser 9 in GSK-3 can be regulated by multiple kinases
(Cross et al., 1995; Fang et al., 2000; Doble and Wood-directly demonstrate that GSK inhibition can convert
a preexisting dendrite into an axon, revealing that the gett, 2003), among which Akt is differentially localized
in axons (Shi et al., 2003; Menager et al., 2004). Topotential for axon formation remains in the dendrites
but is continuously suppressed by active GSK-3. test for GSK-3 regulation by the candidate upstream
two axons boxed in the left panel are shown in higher magnification in the right panel: both were positive in FM dye uptake and release.
Images were taken at the indicated time points before and after stimulation by 90 mM K. The scale bars are 10 m.
(G) Quantification of neurites, with the axon defined as neurites positive in FM4-64 uptake, and dendrites as neurites negative in dye uptake.
The p values were: 0.001 between GFP and GID5-6 (M). (N): no axon. (M): multiple axons.
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Figure 6. Control of GSK-3 Phosphorylation and Neuronal Polarity by Akt
(A) Inhibition of GSK-3 (Ser 9) phosphorylation by the PI3K inhibitor LY294000, but not by the PKA inhibitor KT5720, the PKC inhibitor Bis,
or the MAPK inhibitor U0126. Neurons were cultured for 24 hr before being treated with the inhibitors for 1hr.
(B) The relative pGSK-3/GSK-3 ratios in growth cones. The p value in the difference was 0.001 between DMSO and LY294000.
(C) A hippocampal neuron transfected by Myr-Akt developed multiple axons.
(D) Quantification of polarity defects. The p values were: 0.001 between Akt and Myr-Akt and 0.001 between Myr-Akt and Myr-Akt
GSK-3 S9A.
(E) Neurite number per neuron. (S): neurons with a single axon. (M): neurons with multiple axons. The p values were: 0.001 between Akt and
Myr-Akt (M) in axon numbers and 0.001 between Akt and Myr-Akt (S) in dendrite numbers.
(F) The average axon length was normalized to 100% for Akt. The p values were: 0.001 between Akt and Myr-Akt (S) and 0.001 between
Akt and Myr-Akt (M).
molecules,weused the same inhibitors for PI3Kas those affected by the aPKC inhibitor bisindolylmaleimide I
(Bis), or by theMAPK inhibitor U0126 or thePKA inhibitorused previously for studies of neuronal polarity (Shi et
al., 2003). LY294002 significantly inhibited Akt phos- KT5720 (Figure 6A).
To test for the functional significance of Akt, we triedphorylation at Ser 473 and GSK-3 phosphorylation at
Ser 9 (Figure 6A). LY294002 did not affect GSK-3 phos- to examine the effect of inhibiting Akt by using shRNAs,
but they caused neuronal death (Yu et al., 2003). Wephorylation at Tyr216. In addition to the biochemical
evidences, we also examined the distribution of GSK-3 investigated the effect of increasing Akt activity on neu-
ronal polarity by using Myr-Akt, a constitutively activeand pGSK-3. LY294002 reduced the ratio of pGSK-3
over GSK-3 (Figure 6B). aPKC is another candidate Akt derived by fusion with the myristoylation signal of
Src (Ramaswamy et al., 1999). The wild-type Akt did notGSK-3 regulator (Etienne-Manneville and Hall, 2003;
Shi et al., 2003), but GSK-3 phosphorylation was not affect neuronal polarity (Figure 6D), whereas Myr-Akt
GSK-3 in Neuronal Polarity
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caused the formation of multiple axons (Figures 6C nificant reduction of PTEN expression therefore corre-
lated with the formation of multiple axons.and 6D).
Because GSK-3 S9A should not be phosphorylated To test for a functional relationship between PTEN
and GSK-3, we did two kinds of experiments. The firstby Akt after the substation of Ser 9, we could test for
the relationship betweenAkt andGSK-3 by cotransfec- was to transfect neurons with PTEN and also treat them
with SB415286. SB415286 almost completely reversedtion of GSK-3 S9A and Myr-Akt. GSK-3 S9A could
partially, but not completely, reverse the effect of Myr- the effect of PTEN overexpression on axon-dendrite po-
larity, resulting in multiple axons (Figures 7B and 7D) atAkt on the formation of multiple axons. These results
are consistent with the idea of Akt being upstream of the expense of dendrites (Figure 7E). The second kind of
experiment was to cotransfect PTEN siRNA andGSK-3GSK-3. The partial reversal could result from either
incomplete overlap in GSK-3 S9A and Myr-Akt trans- S9A. The effect of PTEN siRNA on multiple axon forma-
tion couldbe inhibitedbyGSK-3S9A (Figure 7D). Thesefection or the possibility that GSK-3 constitutes a part,
but not all, of the output for Akt. results indicate that GSK-3 is downstream of PTEN in
axon-dendrite polarity formation because GSK-3 ma-Detailed examination indicates that Akt played multi-
ple roles in axon and dendrite development. Myr-Akt nipulations dominate over PTEN manipulations.
One role of PTEN does not seem to be downstream ofincreased the number of neurites per neuron both in
neurons forming multiple axons (Myr-Akt [M]), and in GSK-3. When neurons were cotransfected with PTEN
siRNA and GSK-3 S9A, GSK-3 S9A could not elimi-neurons with single axons (Myr-Akt [S]) (Figure 6E). Myr-
Akt increased both the numbers of axons and dendrites nate axons (Figure 7D, last three bars), suggesting that
either PTEN siRNA can antagonize the effect of GSK-3from the normal total of five neurites to eight. When the
number of axons was increased in Myr-Akt (M) neurons, S9A in axon formation or that GSK-3 S9A has to act
in a PTEN-dependent pathway to inhibit axon formation.axon length was shorter than normal (Figure 6F), per-
haps due to limited materials for an increased number In the latter scenario, GSK-3 activation could be up-
stream of PTEN in inhibiting axon formation.of axons. When the number of axons was not increased
in Myr-Akt (S) neurons, the single axon was longer than
normal (Figure 6F), indicating that Akt promotes axon Discussion
outgrowth. The length of dendrites was not affected by
Myr-Akt (data not shown). Our results have revealed that active mechanisms are
Only the effect of increasing axon number is shared required to maintain as well as establish the axon-den-
between Akt activation and GSK-3 inactivation. GSK-3 drite polarity of mammalian neurons and that GSK-3
is therefore only one downstream component of Akt, plays roles in both establishing and maintaining neu-
specifically mediating the function of Akt in axon-den- ronal polarity. These results provide insights into the
drite polarity, but not in neurite number or axon length. molecular basis of neuronal polarity determination. We
propose a model in Figure 8 which is consistent with
our results as well as those from the accompanyingFunctional Relationship between GSK-3
paper (Yoshimura et al., 2004) and previous papers (Ina-and PTEN
gaki et al., 2001; Fukata et al., 2002; Shi et al., 2003;The phosphatase and tensin homolog deleted on chro-
Menager et al., 2004).mosome 10 (PTEN) is a lipid and protein phosphatase
GSK-3 activity is of central importance. There is nothat functions opposite to PI3K by dephosphorylating
significant difference in GSK-3 activity in the neuritesthe lipid product of PI3K, phosphatidylinositol 3,4,5-tris-
of nonpolarized neurons. However, after the transitionphosphate (PIP3) (Maehama andDixon, 1998).We exam-
from st. 2 nonpolarized neurons to st. 3 polarized neu-ined the role of PTEN further and characterized the func-
rons,GSK-3activity is higher in dendrites than in axons,tional relationship of PTEN andGSK-3. Consistent with
which is critical for determining axon-dendrite polarity.the earlier finding (Shi et al., 2003), neuronal polarity
GSK-3 is regulated by Akt, which is in turn regulated bywas lost upon PTEN overexpression (Figure 7). Detailed
PI3K and PTEN, perhaps through PI(3,4,5)P3 and a kinaseanalysis indicated that PTEN transfection inhibited axon
that phosphorylates Akt. Downstream of GSK-3 areformation (Figures 7A and 7D and Supplemental Figure
CRMP2 and others such as Tau and MAP1B. There areS3 on theCellwebsite) without affecting dendrite forma-
no data at themoment to placePar3/Par6, adenomatoustion (Figure 7E). The inactive PTEN control (PTEN
polyposis coli (APC) (Shi et al., 2003, 2004), or CDC42 andG129R) did not affect neuronal polarity.
Rap1B in this pathway (Schwamborn and Puschel, 2004).To investigate the role of endogenous PTEN, we used
PTEN siRNA, a small inhibitor RNA (siRNA) construct
designed specifically for PTEN (Ning et al., 2004), and Roles of GSK-3 in Establishing and Maintaining
Neuronal PolarityPTEN SsiRNA, a scrambled control. PTEN siRNA, but
not PTENSsiRNA, reducedPTENprotein levels in hippo- The conclusion that GSK-3 plays critical roles in both
establishing and maintaining neuronal polarity is basedcampal neurons (Figure 7F). PTEN siRNA increased the
number of axons (Figures 7C and 7D and Supplemental on observations of pGSK-3 distribution and experi-
mental manipulations of GSK-3 activity.Figure S3 on the Cell website) at the expense of den-
drites (Figure 7E). When the level of PTEN protein was In st. 2 neurons, GSK-3 inactivation (as indicated by
phosphorylation at Ser 9) is similar in all neurites. In st.examined (Figure 7F), the level of PTEN was reduced
by more than 50% in PTEN siRNA (M) neurons with 3 neurons, there is more inactive GSK-3 in axons than
that in dendrites. A constitutive active GSK-3 inhibitedmultiple axons, whereas PTEN was reduced less than
20% in PTEN siRNA (S) neurons with single axons. Sig- axon formation but did not affect dendrite formation,
Cell
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Figure 7. Effects of PTEN and PTEN siRNA on Neuronal Polarity
(A) A neuron transfected with PTEN developed no axons.
(B) A neuron transfected with PTEN and treated with GSK-3 inhibitor SB415286 developed multiple axons.
(C) A neuron transfected with PTEN siRNA with multiple axons.
(D) Quantification of polarity defects. The p values were: 0.001 between PTEN and PTEN G129R, 0.001 between PTEN and
PTENSB415286, 0.001 between PTEN SsiRNA and PTEN siRNA, and 0.001 between PTEN siRNA and PTEN siRNAGSK-3 S9A.
(E) Neurite number per neuron. (S): neurons with a single axon. (N): neurons with no axon. (M): neurons with multiple axons. The p values
were: 0.01 between PTEN and PTEN G129R in dendrite numbers, 0.05 between PTEN siRNA (M) and PTEN SsiRNA in dendrite
numbers, 0.001 between PTEN siRNA (M) and PTEN SsiRNA in axon numbers, and  0.001 between PTEN siRNA (M) and PTEN siRNA
GSK-3 S9A in axon numbers.
(F) PTEN expression levels in the cell body were measured and normalized as 1 for the control untransfected neurons. (S): neurons with single
axons. (M): neurons with multiple axons. The p values were: 0.001 between the control and PTEN siRNA (M) and 0.05 between the control
and PTEN siRNA (S).
indicating thatGSK-3 inactivation is necessary for axon 5 days in this paper). Culturing for longer time makes it
easier for identification with multiple markers and func-formation. Inhibition ofGSK-3 activity by three different
methods (pharmacological inhibitors, a peptide inhibi- tional testing. The shRNA constructs provide strong evi-
dence for the formation of multiple axons upontor, and shRNAs) all resulted in multiple axon formation
with concomitant reduction of dendrite formation, indi- GSK-3 inhibition.
One model is that, during the transition from st. 2 tocating thatGSK-3 inhibition is sufficient for axon forma-
tion. There is a recent report that AR-A014418 and LiCl, st. 3, GSK-3 is activated in all neurites except one.
Activation of GSK-3 in several neurites causes themtwo pharmacological inhibitors of GSK-3, led to loss
of axon formation (Shi et al., 2004), which were different to become dendrites, leaving one neurite with a lower
level of active GSK-3 to form the axon. The alternativefrom effects reported here and in the accompanying
paper (Yoshimura et al., 2004). These apparent differ- model is that GSK-3 is inactivated in axons during the
transition from st. 2 to st. 3.ences might be due to differences in the concentrations
of LiCl used in different labs (5 mM in Shi et al. [2004], Our conclusion that GSK-3 is involved in maintaining
neuronal polarity is based on the findings that preex-1 mM in this paper, and 2 mM in Yoshimura et al. [2004])
and in the length of culture (48 hr in Shi et al. [2004] and isting dendrites from day 3 neurons can be converted
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GSK-3 manipulations predominate over PTEN ma-
nipulations on neuronal polarity, indicating that PTEN is
upstream of GSK-3 in polarity formation. One effect of
PTEN seems to be downstream of GSK-3: activation
of GSK-3 in GSK-3 S9A could inhibit axon formation,
but this effect was blocked if PTEN was inhibited by
PTEN siRNA. It is also possible that there is a feedback
loop between PTEN and GSK-3.
GSK-3 Regulation of Its Targets
There are multiple downstream targets for GSK-3.
Some downstream targets are involved in controlling
cytoskeleton dynamics. The accompanying paper shows
that CRMP-2 is a direct target of GSK-3 and phosphor-
ylation of CRMP-2 decreases its tubulin binding activity
(Yoshimura et al., 2004).
GSK-3 can also phosphorylate other MT-associated
proteins such as MAP1B (Goold et al., 1999; Lucas et
al., 1998), tau (Hanger et al., 1992), and APC. Phosphory-
Figure 8. A Model for a Signaling Pathway in Determining Axon- lation by GSK-3 inhibits the ability of tau and MAP1B
Dendrite Polarity to bind MT and thereby inhibits MT assembly. Hippo-
(A) A neuron developing from the nonpolarized st. 2 to the polarized campal neurons isolated frommice lacking both tau and
st. 3. MAP1B showed strong defects in neuron polarity: they
(B) Diagrams illustrate relative activities ofmolecules in the pathway: could form dendrites but not axons (Takei et al., 2000).
the left panel for the dendrites and the right panel for the axon.
Tau and MAP1B may therefore also be downstream ofGSK-3 activity is higher in dendrites than in axons. Akt activity
GSK-3: GSK-3 inactivation in axonal tips would allowis higher in axons than in dendrites. Differences of activities of
tau and MAP1B to be active and promote MT assembly,endogenous PI3KandPTENwere inferred from results frommanipu-
lating PI3K and PTEN without direct detection. thus favoring axon elongation. In Alzheimer’s disease,
tau is highly phosphorylated in the brain by aberrantly
activatedGSK-3 (Hanger et al., 1992). It will be interest-into axons upon GSK-3 inhibition. This conclusion is
ing to test the significance of axon defects resultingalso consistent with the finding of preferential pGSK-3
from activated GSK-3 in the pathogenesis of Alzhei-localization in axon tips of neurons at stages later than
mer’s disease.2 and 3 (Zhou et al., 2004). This indicates that the poten-
GSK-3 phosphorylation of its substrates usually re-tial to form axons persists in dendrites and that the
quires prior phosphorylation (priming) by other kinases.presence of active GSK-3 in the dendrites suppresses
One priming kinase is casein kinaseI for GSK-3 phos-their axon formation potential.
phorylation of -catenin (Liu et al., 2002; Cho and John-It is not clear whether there is a default fate for neu-
son, 2003) and another is PAR-1 for GSK-3 phosphory-rites. Dendrites have been assumed to be the default
lation of tau in Drosophila (Nishimura et al., 2004a). Asince there are normally more dendrites from each neu-
mammalian Par-1 homolog MARK phosphorylates mul-ron and they grow slower. On the other hand, the effect
tiple MT-associated proteins including tau and triggersof GSK-3 inhibition on dendrites is more consistent
MT disassembly (Drewes et al., 1997). It will be interest-with axons as the default fate, which has to be actively
ing to investigate the role of MARK(s) in determiningand continuously suppressed by GSK-3. It should also
neuronal polarity.be noted that, while there are several ways to make
neurites which normally do not form axons to become
the extra axons, so far there is no manipulation that can Generation of New Axons from Preexisting
convert axons into dendrites. Dendrites and Its Implications
Current approaches to promote recovery of connectivity
after neural injuries aim to regenerate damaged axonsRegulation of GSK-3 in Hippocampal Neurons
GSK-3 has a high level of basal activity, and its regula- or facilitate sprouting from damaged axons. The ability
to convert dendrites into axons by molecular inhibitorstion usually results from inactivationbyupstreamsignals
(Doble and Woodgett, 2003). Phosphorylation at Ser 9 suggests that it will be worthwhile to explore the ap-
proach to generate new axons from dendrites on adultis a major means to inactivate GSK-3. Our results with
Akt and PTEN indicate that both are upstream of GSK-3 neurons with damaged axons.
Before the therapeutic application can be tested, itin determining neuronal polarity. Akt functions to inhibit
GSK-3 whereas PTEN functions to activate GSK-3. will be necessary to investigate the feasibility of using
GSK inhibitors to convert dendrites into axons in vivoOur results also provide evidence that Akt plays more
roles than neuronal polarity because its activation could and in adult animals.
The availability of pharmacological inhibitors ofalso increase the number of dendrites and the length of
axons, neither of which could be caused by GSK-3 GSK-3 as well as inhibitors based on DNA and siRNA
provide a range of potential therapeutic reagents forinactivation. They indicate that these roles of Akt aremedi-
ated by downstream components other than GSK-3, future tests. GSK-3 inhibition therefore offers a novel
approach that may be used to induce axon conversionwhich only mediates the role of Akt in neuronal polarity.
Cell
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